Clearside Biomedical, Inc. (CLSD, Financial), a biopharmaceutical company focused on innovative ophthalmic disease therapies, is drawing the attention of Wall Street as analysts see substantial upside potential for the company. On Thursday, shares closed at $0.93, down 4.12%, in a 52-week range of $0.92 to $2.12. The consensus average price target is $6.00, and the potential upside is over 500%.

The SCS Microinjector® is Clearside's proprietary technology that enables the delivery of treatments to the back of the eye through the suprachoroidal space (SCS). Pivotal to developing its leading pipeline asset, CLS-AX, the platform that facilitates in-office and repeatable procedures, has been a key enabler. Now undergoing Phase 2b clinical trial completion Phase 3 planning for the treatment of neovascular age-related macular degeneration (wet AMD), this axitinib injectable suspension has been specifically developed.

XIPERE®, Clearside's first FDA-approved product for suprachoroidal injections, is commercially available through a partner in the US. Together, Clearside's strategic partnerships extend the use of its SCS injection platform for further therapeutic discoveries focused on the retina and choroid.

Nevertheless, the stock holds six analysts with strong buy ratings, for a score of 4.83 over the past three months. Clearside is investing more time and money into expanding its commercialization efforts and is closely monitored by investors as the company plans its next phase of clinical trials.